Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Edwards Lifesciences (NYSE:EW) but lowers the price target from $101 to $90.
July 26, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Edwards Lifesciences but lowers the price target from $101 to $90.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100